Abstract The following is a brief overview of the present stage of development of chemotherapy of viral diseases,
INTRODUCTION
The important strides of the past few years have firmly established the feasability of chemotherapy of viral diseases, and the major complaint now is that progress is slow. But the long and tortuous pathway from the laboratory to the clinic applies to all new drugs, due at least in part to public insistence on "totally safe drugs". The resulting regulations have been concisely analyzed in a recent article under the title "An end to the search for new drugs?" (1) . Amongst the numerous reviews on the subject of antiviral agents, that of Bucknall and Rutty (2) most systematically describes the problems that must be coped with.
There are presently 5 drugs licensed for viral chemotherapy in the U.S.A, and several more in other countries. Others, potentially superior to those now in use, are undergoing clinical trials. What is most encouraging and stimulating is that current research is accompanied by serious efforts, at least partially succesful, to delineate mechanism(s) of action. In contrast to research in the field of tumour chemotherapy, where it is still difficult to pin-point targets which differentiate a neoplastic from a normal cell, the molecular biology of viral replication has made phenomenal progress, so that one may now envisage the selection of appropriate targets for interfering with the cycle of viral replication with minimal toxicity to the host cells. To a considerable extent, this is based on a consideration of the enzymes involved in the disease process.
One of the most striking, indeed fascinating, recent discoveries (see ref. 3 for review) relates to influenza virus, the RNA transcription of which exhibits an absolute dependence on a primer consisting of a 5'-terminal capped fragment 10-13 residues in length derived from newly-synthesized host cell mRNA. This explains why viral RNA replication is dependent on the functioning of host-cell nuclear RNA polymerase II. The virion contains an endonuclease which recognizes and cleaves these fragments from cellular mRNA. Characterization of this nuclease, and its mechanism of action (see ref. 4) , may prove useful in the design of an anti-influenza drug.
A similar approach is being widely applied in parasitic chemotherapy, where at least 10 potential targets are now known (5) . One of these is based on the fact protozoan parasites are deficient in synthesis of purine nucleotides, so that purine salvage pathways become essential for survival 424 D.SHUGAR and growlh. Among the Leishniania spp. one unique salvage enzyme is a purine nucleoside phosphotransfrase wtiich transfeis phosphate from a variety of donors to the 5' of purine nucleosides. Tbis enzyme, which may be considered a formal counterpart of herpes virus pyrimidirie deoxyriucleoside kinase (see below), readily phosphorylates exogenously administered nucleoside analogues such as the ribosides of allopurinol and thiopuririol, and forrnycm B. These, in turn, are either converted intracellularly to the triphosphates to become incorporated into nucleic acids of the parasite, or are inhibitors of other essential enzymes in parasite purine metabolism. The foregoing three nucleoside analogues, the more interesting in that they are relatively non-.toxic to mammalian hosts (which lack the same enzyme), are potent antileishmanial agents both vitro and j vivo. It is worth noting that such phosphotransferases, also available from Tts and inicroorganisiiis, furnish a convenient tool for phosphorylation of nucleosides, particularly in those instances where chemical methods pose difficulties (6).
INITIAL SCRKENING
The search for antiviral agents is based, as for other drugs, on initial screening, in a suitable j vitro test system, of "selected" products. The selection systems include: (a) products of natural origin, (b) "off-'the--shelf" chemicals, and, now more widely applied Cc) compounds which may be logically anticipated to interfere with some key metabolic pathway(s). Once a compound with some activity has been located, it may be chemically modif-. ied and the resulting analogues compared for activity, cytotoxicity, etc.
(structure-activity relationships, SAR). Screening procedures have become relatively rapid and efficient and, while procedure (c) may appear to the researcher esthetically more rational and satisfying, both (a) and, especially, (b) have many proponents. Two such "off--the--shelf" antiviral agents are amantadine, now licensed for use against influenza A, and phosphonoactate (PAA) which led to phosphonoformate (PFA), a promising antiherpes agent undergoing clinical trials. Procedure Cc) led to the multitude of promising nucleoside analogues presently under intensive study, several of which are now licensed for clinical use, 5-iodo-2'-.deoxyuridine, 5-.trifluoro--2'-deo--xyuridine, araA and acycloG (acyclovir) in the USA, and several others, including 5-ethyl.-2 '-de oxyuridine, in Europe.
PRODUCTS OF NATURAL ORIGIN
In contrast to the situation prevailing in the field of tumour chemotherapy, products of natural origin, reviewed by Swallow (7) and Becker (8), have hitherto not played an important role in the development of antiviral agents (but see below, for interferons). A possible exception is araA, presently licensed for systemic use in proven cases of herpes encephalitis.
Originally synthesized chemically as a potential antitumour agent, like 5-iodo-2 '-deoxyuridine (IUdR), it was found to exhibit significant antiherpes activity. The difficulties associated with the large-scale chemical synthesis of this compound were subsequently circumvented by development of a fermentation procedure (9) based on the ability of Streptomyces antibioticus to convert exogenous adenosine to araA, presumably via a 21-.epimerase;
an adenosine 2 -epimerase, which converts adenosine to araA j vitro, has now been isolated (Suhadolnik et al., cited in ref. 10 ). Other, less effective, fermentation processes have been described.
Enzymatic synthesis of D-ar abinonucle oside s A general procedure f11J for the vitro enzymatic synthesis of purine D-.arabinonucleosides, including araAwith the required purine base and the readily available 2,2'-anbydro-araC as starting materials, is based on the following sequence of reactions: (a) alkaline hydrolysis of 2,2'-anhydro--araC to araC, (b) deamination of araC to araU with cytidine deaminase, (c) phosphorolysis of araU with uridine phosphorylase to liberate O(-D-arabinofuranosyl-1-phosphate, (d) reaction of the sugar phosphate with the required purine base, catalyzed by purine nucleoside phosphorylase. The overall yield, for araA, was 80%, but the procedure requires three purified enzymes from .
and is probably not a serious competitor of . antibioticus.
It is, however, a useful laboratory-scale method for other biologically important, but not readily accessible, analogues, e.g. the D-arabinoside of 2,6-diaminopurine, obtained in 60% yield. Furthermore, the procedure may be simplified by elimination of the first enzymatic step since, in acid medium, araC undergoes deamination at a rate 50-fold higher than that for cytidirie, due to Intramolecular catalysis by the "up" 2'-.OH, formation of a cyclic intermediate with C(6). This has been profited from to quantit-. ively deazninate a variety of araC analogues with a free 2'-.OH in acetic acid at elevated temperature (12) . Theforegoing may, however, become out-. dated by a new general procedure for the chemical synthesis of xylofuranosyl and arabinofuranosyl riucleosides via selective protection and oxidat-.
ion of the ribose ring of ribonucleosi (13) .
Natural products from marine sources Rinehart et al. (14) have presenidTh systematic account of the results of two expeditions designed to examine extracts of marine species, from Baja California and the Caribbean, for various biological activities. Initial tests, performed directly on shipboard, revealed a surprisingly large number of extracts with significant antiviral activities. Continuing studies on shore, still in progress (15, 16) , led to isolation and identification, in a Caribbean tunicate of the family Didemnidae, of a class of depsipeptides, shown in Fig. 1 , with significant activities against a variety of RNA and R -MeLeu -* Tbr -Sta -+ Hip -+ Leu -+ Pro -+ Me2Tyr DNA viruses. The structures of the peptides were established by means of hydrolysis, NMR spectroscopy and gas chromatography/mass spectrometry (14) .
In j vitro tests, didemnins A and B inhibited growth of HSV.-1 and HSV-2 at concentrations of 1.0 and 0.5 uM, respectively; and both conferred protection on mice infected with Fift Valley fever virus, albeit with a low therapeutic index, B being several times more effective than A, in agreement with the in vitro results with HSV. It was pointed out that the difference in activiTIes between A and B, combined with their structural complexities, provides opportunities for chemical modifications. Both A and B were only moderately effective against cutaneous HSV infections in mice, and inactive against Semliki Forest virus. Further reports on this interesting class of compounds are anticipated. A more recent study describes the isolation, from the Caribbean tunicate Eudistoma olivaceum, of another class of compounds containing the hitherto unreported condensed oxathiazepine ring system, two of which were potent vitro inhibitors of HSV-1 (17) .
Pokeweed antiviral protein
Many plants contain proteins, with ability to inactivate ribosomes, and associated with the A-chain of plant toxins, but lacking the B-chain, so that they do not bind to the surface and of mammalian cells and are therefore not potent toxins. The first such protein to be detected, discovered by virtue of its ability to reduce infectivity of tobacco mosaic virus, was isolated from Phytolacca iericana (pokeweed) and is referred to as pokeweed antiviral protein. ]ts znolecuIr weight is about 28,000 and it is slightly basic in nature (p1 = 8.1). Its mechanism of action against RNA viruses, such as influenza and polio, appears to be based on ability to penetrate infected cells and to inactivate 60S ribosomes, thus inhibiting viral protein synthesis. In HSV-infected cells, the mechanism of action is more complex and includes inhibition of viral DNA synthesis. Proteins from a number of other plant species have been isolated and found to display similar properties (see ref. 18 only in rather impure form, and in extremely limited quantities, and it is, therefore, not surprising that reported results on clinical efficacy were frequently conflicting. In the past 3-4 years marked amelioration of classical isolation techniques, and the development of succesful reconibination methods, have made available adequate quantities of these interferons and some of their sub-.classes for both fundamental investigations and clinical trials, both as potential antiviral and antituxnour agents. However, while the "great ezpectatrOiii"presently prevailing for the therapeutic uses of interferon do have a sound theoretical basis, there are as yet no unequivo... cal results forthcoming from clinical trials. Some findings are, indeed, promising, e.g. O'-interferon prophylaxis aa1nst cytomegalovirus syndromes in high-risk patients (19) , but even these still require independent confirmation. A useful innovation is the organization, by the WHO, of an intern-. ational committee for establishment of Interferon standards, methods of assay, and reporting of results so as to permit of direct comparisons of findings from different laboratories (20) .
The (2-5)A system. The multitude of biochemical pathways of interferon action, which vary for different viruses, bave been most recently reviewed by Sen (21) . A development of particular interest to chemists and biochemists was the discovery by Kerr et al. (22) that interferon treatment of cells in culture induces, along with the antiviral state, a number of proteins, one of which is the so-called (2-5)A syrithetase. This is an enzyme which strongly binds, and is activated by, double-stranded RNA to synthesize from ATP a unique 2',5'-linked oligoadenylate, ppp(A2'p)A (n 2, with high activity for n 3) . This, in turn, activates a latent endoribonuclease (Iase L) that effectively degrades single-stranded mRNA, leading to potent inhibition of protein biosynthesis at nanomolar concentrations (22) , as shown in Fig. 2 parallel the development and decay of the antiviral state, although there is also evidence that the (2-5)A system is equally involved, like interferon, in other cellular processes such as regulation and differentiation (22) .
Antiviralagents 427
The foregoing points to the possibility of profiting from (2-5)A, and/or ehenilca]. and structural analogues, to achieve antiviral activity without use of interferon. Various (2.-5)A analogues have now been synthesized and their activities examined (see, e.g. ref. 23 ). However, a proper assessm ent of results in cellular systems must take account of the relative imp.-ermeability of the cell membrane to the highly charged (2.-5)A molecule, as well as its susceptibility to degradation by hydrolysis of the internucleotide linkages by phosphodiesterase(s), and of the terminal 5'-triphosphate by dinucleoside polphosphatases.
The adenosine moiety appears to be an important requirement for activity. The unique 2',5' phosphodiester linkages are essential for binding to RNase L, and accompanying inhibition of protein synthesis. Replacement of only one of these linkages by a 3',5' bond led to a decrease in activity of an order of magnitude, and the (3.-5)A analogue exhibited 10'5 the activ.-ity of (2-.5)A (24) . It is also of interest that (2.-5)A is a relatively pot-. ent inhibitor of both vaccinia virus and cellular mRNA(guanine-7)methyl-' transferases, the enzyme which methylates the GMP cap of mRNA, albeit only at u4 concentrations. But 3'-.O-methyl analoues, methylated at the terminal 3'..OH or at all three 3'-hydroxyls of pppA2 p5'A2'p5'A, and with a varying number of terminal 5'-.phosphate groups, were not only 10.-fold more active than the parent (2.-5)A, but selectively inhibited the viral enzyme, e.g. pppAAAxn inhibited the viral enzyme by 60% at a concentration which was without effect on the cellular enzyme (25) . Relevant to the foregoing is the fact that the 5 '-triphosphate of the triazole ribonucleoside ribavirin is an inhibitor of vaccinia virus mRNA guanyltransferase (see below).
It has been found that modifications of the 2'-'terminus are relatively well tolerated. This was profited from to convert the 2'.-terminal ribose of (2.-5)A-tetrarner to an N-.hexylmorpholine ring (by periodate oxidation to a dialdehyde, followed by reaction with hexylamine and reduction). The resulting analogue was 5 to 10.-fold more effective as an inhibitor of translational activity, presumably because of its more pronounced resistance to enzymatic degradation (23) . However, this analogue still does not readily traverse the cellular membrane.
An additional interesting activity of (2-.5)A synthetase, at least in vitro, is its ability to add 5'.-AMP in 2',5' linkages to such important mabol.-ites as ADP-.ribose, NAD and A5'p 5'A. The product with the latter is A5'p5'A2'p5'A2'p5'A, or adenosin "capped" (2-5)A (26) . A series of such A.-caped analogues of (2-.5)A, synthesized chemically, turned out to be relatively stable under conditions of the protein synthesis assay, while capping did not appear to adversely affect binding to flNase L, but did not lead to activation of the latter ç27). Perhaps the most significant finding was that, whereas A5'pft5'A2'p5'A2 p5'A was stable to human serum, it was rapidly hydrolysed by human Nalrnalwa cell extracts to p5'A2'p5'A2'p5'A and ppp5'A2'p5'A2'p5'A. This points to the possible use of A-capped (2-5)A as a depot form of the latter. Furthermore, the formation of only two products in the decapping reaction in Nalmalwa cells suggests that the enzyme invol-.
ved is one of a class of dinucleoside polyphosphatases, in this case the specific dinucleoside tetraphosphatase identified in a variety of cells, the products of which are a nucleoside 5'-phosphate and a nucleoside 5'-. triphosphate (28) . A similar enzyme has been purified from higher plants (29) . The specificity of potato tuber nucleotide pyrophosphatase, which can decap intact mRNA, towards various dinucleoside polyphosphates has been recently examined (30) .
Removal of the highly charged 5'-terininal triphosphate from (2.-5)A, gives (A2'p)2A, referred to as (2.-5)A.-core, which should theoretically more read-. ily penetrate intact cells. While some biological activity has been report.-ed for (2-.5)A-core, including inhibition of DNA synthesis, attempts to do.-monstrate antiviral activity have been negative. It was subsequently found that the zyloadenosine analogue of (2.-5)A core, (XyloA2'p)xyloA, exhibits antiviral activity HSV types I and 2, a finding originally ascribed to its higher resistance to enzymatic degradation than (2-5)A.-core, but subs-. equently found to be due to slow degradation, with release of xyloAMP which, because of its resistance to deamination by adenosine deaminase, is more effective than xyloA (31) . The foregoing also suggests that the core penetrates at least viral-infected cells. A somewhat analogous situation may prevail for the cordycepin (3 '-de oxyadenosine) analogue of (2-'5)A-c ore, initially reported to inhibit transformation by Epstein-Barr virus, and to inhibit DNA synthesis in mouse 3T3 fibroblasts more effectively than 428 D. SHUGAR (2-.5)A-core. Ii; now appears that these activities are due to a sustained enzymatic release of cordycepin nucleotides (32) .
Vaccines
PEese do not formally fall within the scope of this presentation, since vaccines are prepared for prophylactic purposes. Effective chemotherapy may eliminate the need for a given vaccine, and this is obviously a desirable goal. It should, however, be noted that there are instances where development of a vaccine poses formidable, if not in some cases insurmount.-able, problems. A case in point are the rhinoviruses responsible for the common cold, where the number of serotypes is so large, and identification of each type frequently so difficult, as to require a considerable number of vaccines to cope with the specificity of the immune reaction. Furthermore, the development of new vaccines by classical methods has become increasingly arduous and costly. A new vaccine was approved in 1981 by the FDA in the USA against hepatitis 13. But the cost of production of this vaccine, from hepatitis B surface antigens isolated from the blood of carriers, is so high that its use is very limited, only to those at high risk. And last, but by rio means least, this was the first new clinically approved vaccine in 10 years.
A new exciting development, of major interest to the natural products chemist, is the finding that antigenic determinants in a protein may be mimicked by short carrier-linked peptides, and that antibodies against such peptides recognize the corresponding sequence of amino acids with either the native or denatured protein. Hence, with only a restricted number of sites on the viral surface of importance as targets for neutralizing antibodies, it becomes feasible to produce synthetic analogues of these regions (a) by expression of viral proteins in recombinant heterologous cells, or (b) by chemical synthesis of the required short peptide sequences. Both of these approaches are now being intensively investigated. In particular, two out of seven chemically synthesized peptides, spanning the regions 141-160 and 200-213 of the VPI polypeptide of foot-and-mouth disease virus, produced high levels of neutralizing antibodies on multiple innoculation into cattle and rabbits. Subsequent single innoculations in guinea pigs demonstrated that peptide 141-160, at levels as low as 200 ug, conferred complete protection against infection (33) . ihile there are numerous associated problems to be resolved before the use of such vaccines in humans (34) , such as the present need for a carrier, and of adjuvante, widespread efforts are already under way to produce synthetic vaccines against other viruses such as polio and even herpes, with very recent impressive results reported for hepatitis B (35) , where a peptide sequence of 26 amino acids was effective. In fact, the resulting antibodies elicited by this vaccine are already being distributed for utilization for diagnostic tests. Furthermore, with present developments in the design and synthesis of biologically active polypeptides (36) , one may envisage chemical modifications of synthetic antigens with the aim of modifying or enhancing their activities.
AMANTADINE
This tricyclic primary amine (1-aminoadamantane .HC1, amantadine.HC1, Symmetrel, see Fig. 3 ) is an off-the-shelf compound uncovered during random screening as far back as 1963. It has had a chequered career regarding its efficacity in prophylaxis and therapy of influenza A infections. It was initially licensed in the USA in 1966, but for use only vs the Asian H2N2 strain, and subsequently against all A strains; and was ?rly widely tested Fig. 3 . Amantadine.HC1 and Rimantidine.HC1. Amantadine is by no means an ideal drug against influenza. However, ir 1979 an exhaustive exanination of available data by an interzational panel conv ered by NIH led to a recommendation for its widespread use for prophylaxis and therapy against all strains of influenza A (it is inactive against B straiis). Also trnderlined was the necessity of accelerated research on amantadine analogues, in particular rimantidine. The latter now appears likely to replace amantadine because of fewer side effects, particularly lower CNS toxicity, most pronounced in older patients particularly suscept.-ible to respiratory diseases.
Although extensively investigated, the mechanism of action of amantadine remains to be clarified. It is apparently one of the few antiviral drugs which is not metabolized in the cell, and acts as such. There is also some evidence that it interferes with the process of penetration through the cell membrane. However, under conditions where penetration has been established (by electron microscopy), synthesis of virus.-specific RNA arid early poly.-peptides could not be detected, suggesting that its site of action is at the stage of viral uncoating, or shortly thereafter (38) . It is, indeed, surprising that more effort has not been devoted to this aspect, following its approval for widespread use in 1979. These aspects, and problems invol.-ved in clinical applications, were most recently reviewed by Oxford (39) .
There are, at the moment, no better candidates against influenza, but din.-ical trials are under way with ribavirin (see below).
PYROPHOSPHATE ANALOGUES
It was long ago noted that some pyrophosphate analogues exhibit antiviral activity, the most active being phosphonoacetate (PAA, Fig. 4 because it exhibits pronounced dermal toxicity and is also deposited in the bone, it has not progressed beyond animal trials (40) . It was subsequently found that another analogue, phosphonoacetate (PFA), is equally or even more active against some viruses, and much less toxic, and it is presently undergoing clinical trials for topical herpes infections (reviewed in ref. 41 ). Its potential systemic use for herpes and other viral diseases is in abeyance pending clarification of the effects of deposition in bone.
Both PAA and PFA are almost unique in that they act as such without being metabolized in the cell, their mode of action involving preferential inhibition of viral DNA synthesis in infected cells. vitro studies have shown that these compounds interact with DNA (and, to a lesser extent, RNA) polymerases at the pyrophosphate binding site, and are non-competitive inhibit-.
ors with respect to nucleoside triphosphates, and competitive inhibitors of the pyrophosphate exchange reaction. Host cell DNA polymerase 0< but not polymerases and X, is also affected, but to a much lesser extent, the K.
for inhibition being up to 30.-fold lower for herpes and some other viral '
polymerases. These findings have been further substantiated by genetic evidence (ref. 42 and references therein). It would nonetheless be of interest to examine the potential role of PAA and PFA in at least a few of the multitude of other biochemical reactions which involve pyrophosphate intermediates. It should be noted that phosphonates are fairly widespread in living cells and are the subject of growing interest (44) . PFA has been reported to be a moderate inhibitor of influenza RNA polymerases (41) .
PM and PPA are relatively highly charged molecules at physiological pH, and one might therefore expect that they would not readily traverse the cell membrane (43) . Their activities in vitro and in vivo indicate that they do, and it would be of obvious interesto estabThTi to what extent they are taken up by normal and infected cells. No such data are presently available. It should be noted that, for PAA, pK1 (POH) = 2.30, PK2 (cOOH) = 5.40, and pK3 (P-OH) = 8.60 (40) , whereas for pFA the correspond.-ing values are pK1 (P...QH) = 0.49, pK (COOH) = 3.41, pK3 (P-OH) = 7.27 (41) . Hence at physiological pH PAA is appreciably less charged than PFA (in fact PAA is almost entirely in the form of the disodium salt, whereas 50% of PFA is the trisodium salt), and this may account in part for the observed differences in activity between the two. Aliphatic and aromatic mono.-, di-and triesters of PPA have been prepared and their activities examined (45) . None of them inhibited HSV.-1 DNA polymerase in vitro. How.-ever, several exhibited effective antiherpes activity. It fIlows that the esters undergo hydrolysis (probably by non-.specific esterases) following entry to the cell. Presumably they would more readily traverse the cell membrane, followed by enzymatic release of PFA, but none of them was more effective than the parent PFA (45) . It had previously been found that phos-. phonates and alkyl esters of nucleotides were usually no more active than the parent nucleosides, and in some instances less so (for review, see ref. 
BENZIMIDAZOLE ANAL0GUES ENVIROXIME
Enviroxime, the and isomers of which are shown in Fig. 5 , is cited here as a striking example of the problems that are encountered on the pathway from the lab to the clinic. Antiviral activity of benzimidazole analogues was noted more than 30 years ago. A highly organized and concerted effort by DeLong's group at Eli Lilly led to the two isomers of enviroxime (47) . The significance of this new analo-. gue resides in its high j vitro activity against all picornaviruses tested and, in particular, againstiIl 43 of 43 rhinovirus types (subsequently extended to over 65), the isomer being about 10.-fold more effective. The interest associated with this finding may be gauged from the difficult.-ies accompanying the clinical diagnosis of type and strain of rhinovirus, and the consequent attendant problems involved in the development of a vaccine against the common cold. Tests on blood and lung levels in mice and dogs, and activity in rhinovirus-infected human organ cultures, all appeared promising. But there has been a sparsity of data on therapeutic indexes. It now appears that this promising compound may not be effective in clinical trials, although final reports must be awaited.
NUCLEOSIDE ANALOGtTES
The high priority presently accorded to nucleoside analogues as antiviral (and, to some extent, antitumour and anti-parasitic) agents is based on the rationale, which can be traced back to Hitchings in the 1940's, of using purine and pyrixnidine analogues for possible interference with nucleic acid metabolism. Pathways for incorporation of purines and pyrimidines into nucleic acids were little known at the time. But Hitchings selected this Antiviralagents 431 approach, at least in part, as "an appropriate quiet backwater where a small group might work relatively undisturbed by the pressures of intensive competition" (see ref. 48 ). We no longer have the "quiet backwater", but we do possess considerable knowledge of the biosynthetic steps involved in the synthesis of nucleic acids, including viral nucleic acids, as well as a multitude of nucleoside and nucleotide analogues which can interfere in Icnown manners at various stages of these pathways.
It should be noted that nucleosides in general readily traverse cell membranes. Furthermore, as will be seen from what follows, antiviral activity of nucleoside analogues is frequently dependent on their prior intracellular "activation", or phosphorylation, by cellular and/or viral kinases, and frequent reference will be made to virus specific kinases which, in a number of instances, are decisive in determining the activity of a given analogue.
The multitude of nucleoside analogues hitherto synthesized and tested for antiviral (and frequently for antitumour) activities is too extensive to even summarize here. The following discussion is limited to several illust-. rative examples, with emphasis on chemical and biochemical aspects (bearing in mind that clinical aspects are the subject of another session at this Symposiuii. high antiviral activity, and which are presently the centre of interest, also illustrates some of the modifications introduced by synthetic methods. Reference may be made to specialized reviews, e.g. a recent one on 5-substituted pyrimidine nucleoside analogues (49) . unaffected. Subsequent to the foregoing, it was shown that BVdIJ also inter-S feres with the g].ycosylation of HSV.-1 late polypeptides (53) . The mechanism of this inhibition remains to be clarified, but could conceivably be med.-iated via interference with the nucleotide coenzymes involved in carbohyd-' rate shesis.
Relevant to the foregoing is the findings of Barr et al. (54) that BV.-dTThP, the initial product of phosphorylation of BVdU is an excellent "substrate" for thymidylate synthetase, which catalyzes conversion of the nucleotide to three diastereomeric products which were isolated and characterized. This reaction may not be of particular significance in HSV-.1 infected cells, in which the viral kinase phosphorylates BVdU directly to the 5'.-pyrophosp-' hate. However, in HSV.-2 infected cells the viral kinase phosphorylates the nucleoside only to the 5'.-monophosphate, which may then be subject to attack by cellular thymidylate kinase before it can be further phosphorylated by cellular kinase(s). This may partially account for the lower pot-. This triazole nucleoside bears a formal structural resemblance to adenosine or guanosine (and even more so inosine), dependon the orientation of the carboxamide group at the ring C(3), as shown in Fig. 8 . It has been the centre of attention for some time, and has undergone clinical trials in various countries (see refs. 55,56 for reviews), but with conflicting reports. Its continued interest stems from two facts; (a) its unusually broad spectrum of in vitro activity, embracing both RNA and DNA viruses, and (b) its potentTl utility against both influenza A and B, either alone or in combination with other drugs such as ainantadine or rimantidien, and respiratory syncytial virus, by continuous aerosol delivery (e.g. ref. 57 ).
The possible mechanism of action of this compound still is to elucidated, but undoubtedly is not the same for all the viruses it is capable of inhibiting vitro. Following entry into the cell, it is initially phosphoryl-.
ated to thèT"-.phosphate by adenosine kinase, but it is possible that other kinases may be involved as well. It is subsequently phoephorylated by cell- age, it was for a while considered that this activity, which would lead to a decrease in the GMP pool (IMP //-) XP -p GMP), accounted for inhib-.
ition of viral replication. However, it is unlikely that inhibition of this enzyme could be specific enough relative to cellular metabolism; and it was subsequently shown to be untenable by the finding that a related thiazole analogue, which equally inhibits this enzyme, exhibits only minimal anti-.
viral activity (58) .
It was subsequently found that the 5'-triphosphate of ribavirin is a reasonably good inhibitor of vaccinia virus mRNA guanyltransferase (K"30 pM),
i.e. the initial step in capping of mRNA, by transfer of GMP from GTP to the 5'-terminus of viral mRNA (59) . Again, however, there is no evidence that this inhibition is selective, or even preferential, for viral mRNA as compared to cellular mRNA. This finding clearly warrants further study with additional viral systems. By contrast, the 5'-triphosphate has been report-. ed to be a selective inhibitor of influenza RNA polymerase (60) ; while the concentration required for 50% inhibition is rather high ("-100pM), such inhibition is in line with the reported activity of ribavirin against inf 1-.
uenza virus (see above).
Particularly interesting was the observation that ribavirin inhibits assembly of mature infectious particles in Sindbis virus-infected Aedes albonictus cells (61) . Infectious RNA synthesis proceeded normally, nucleocapsids were assembled, and envelope proteins synthesized and normally glycosylated. But no assembly of infectious virions occurred. Similar results were found with vaccinia, a DNA virus. This is one of the very few, if not only, instance of inhibition of assembly, and it is indeed surprising that it has not been further investigated. Relevant to this is the subsequent finding that ribavirin inhibits popypeptide synthesis of Simian (SAil) rotavirus vitro and of murine rotavirus gastroenteritis (62) .
Like chioramphenico, 3-.atnino-1,2,4-triazole inhibits protein synthesis on mitochondrial ribosomes. Since the aglycone of ribavirin, 1,2,4-triazole-3-. carboxamide (hence an analogue of 3-amino-1,2,4-triazole) also exhibits some antiviral activity (perhaps by conversion to the nucleoside by a nuci-. eoside phosphorylase, followed by phosphorylation to the nucleotide), it is conceivable that it is active as such by inhibition of protein synthesis. The foregoing by no means exhausts all the possible mechanisms of action of ribavirin, and undoubtedly accounts in part for its broad spectrum of antiviral activity. Furthermore, it would be of interest to establish whether the 5 '-triphosphate of ribavirin is a substrate for RNA polymerase and whether it undergoes incorporation into RNA. On the basis of results of clinical trials, this conpound has been approved for topical treatment of herpes keratitis. It is also the first antiviral agent to be licensed for systemic use, in treatment of proven cases of herpes encephalitis, varicella zoster virus infection in immunocompromized patients, and is under consideration for approval for therapy ofneonatal herpes.
Notwithstanding the foregoing, the precise mechanism of action of this analogue is not clear. Intracellularly it is phosphorylated stepwise to the triphosphate, principally by cellular kinases. The extent of involvement of viral kinases, if at all, remains to be established. The 5'.-triphosphate is a preferential inhibitor of HSV DNA polymerase, but is incorporated into both viral and cellular DNA. It is also an inhibitor of ribonucleoside diphosphate reductase, of RNA-dependent RNA polymerase, and several other enzyme systems (reviewed in ref. 64 ).
Although araATP slows DNA elongation, it is now reasonably well established that it is incorporated internally into DNA, but not RNA, and that such DNA is inherently more alkali labile than normal DNA, as a result of strand scission at the 3'S-carbon of the incorporated arabinosyl sugar without degradation of the araA moiety itself (65) . It is conceivable that such incorporation, and accompanying lability, may be more pronounced with viral, relative to cellular, DNA. In general, it is somewhat disconcerting that the mode of action of one of the most widely approved antiviral agents is pres ently so ill-defined, and represents a real challenge to further progress along rational lines (66) .
Indeed, if a quantitative comparison is made between different nucleosides for in vitro antiviral activity and cytotoxicity (Table 1) , it will be seen that araA appears the least promising against I-ISV--I and HSV-2, although Table 1 , the high activities of BVdU, FIAC and acycloG (Fig. 6) and their low cytotoxicities. Attention should also be drawn to one of the earliest and simplest of thymidine analogues, 5-ethyl--2'---deoxyuridine (68, 69) , which is still a reasonable candidate against HSV-1 and HSV-2, and is in fact licensed for use in several European countries. Bole of viral kinase. The key role of the viral thymidine/deoxycytidine kinase is underlined by the fact that acyclovir is inactive against pseudo--rabies (a member of the herpes group) and vaccinia viruses. However, in host cells biochemically transformed so that they express the 11511-I kinase gene, the drug is equally effective against both these viruses. It follows that the kinase activities of pseudorabies and vaccinia viruses, which differ from each other and from the corresponding cellular kinases (74) , also differ distinctly from HSV kinase; and that the triphosphate of acyclovir is an effective inhibitor of pseudorabies and vaccinia DNA polymerases. The differences in specificities of the viral kinases also account for the narrow spectrum of antiviral activity of acyclovir. While at first sight unusual that a viral thymidine/deozycytidine kinase phosphorylates a nude--oside analogue with a purine base, it should be noted that the so-called deoxycytidine kinase of calf thyinus also phosphorylates deoxyadenosine and deoxyguanosine (75) . The adenine analogue of acycloG, and acyclonucleosides with pyrimidine bases, are very poor substrates for HSV kinase (72).
91.3-dihydroxjy-2-propoxymethyl)guanine (DRPG) Extensive structure-activity relationships led to the almost simultaneous synthesis in several laboratories of DHPG (76, 77, 78) , depicted in Fig. 9 . This compound is reported to be a much more effective substrate for HSV-1 thymidine kinase, with a value of Vm/Km 3O$old higher than for acyclovir, while the inonophosphate is a more erfective substrate for cellular GMP Icinase, the V/K being almost 500-fold that for acycloGMP (78) . The result is more rapid formation, in infected cells, of the triphosphate, which is as effective an inhibitor of the viral pol.ymerase as acycloGTP.
vitro results have been forthcoming at a rapid pace, and are all consistet1ypromising. The analogue is as effective, or more so, against HSV-1, HSV-2 and VSV, than the parent acyclovir, and also exhibits a broader spe ctrum of activity in that it is also effective against human cytomegalovirus and Epstein.-Barr virus at concentrations that do not affect cell growth ('9). Results of animal tests from two different laboratories under-. line its low cytotoxicity in mice and up to a 50-fold higher efficacy in treatment of systemic or local HSV-1 infections or HSV-.2 intravaginal infe ctions.
More detailed in vitro studies showed that activity vs HSV-1 is dependent on induction a properties of the viral thymidine kiase. Virus variants with altered kinase, resistant to acyclovir, retained their sensitivity to DHPG, which was also active against 5 different HSV variants with altered DNA polymerase activities and resistance to acyclovir. Particularly inter-. esting was the finding that DBPG was incorporated internally into DNA strands (80) . In cytomegalovirus-.infected cells, DHPG, at concentrations of 2-4 pJ, not only suppressed viral DNA synthesis, but also inhibited the synthesis of 6 virus-.specific polypeptides, whereas concentrations up to 100 pM did not affect uninfected cell macromolecular synthesis or cell growth (79) . Since there are still doubts as to whether human cytomegalovirus encodes a specific thymidine kinase, the mechanism of action of DHPG may differ from that against HSV. While it is too early to predict the clinical utility of DHPG in HSV infections, its potential use against cytomegalovirus infections is at the moment under investigation.
3'-Branched and °(-anomeric nucleosides. The surprisingly more rapid rate of phosphorylation of DHPG, relative to acycloG, by the viral kinase is possibly relevant to the behaviour of 3'-branched analogues of the antitumour compound 6-thio--2'-deoxyguanosine (TGdR) described by Acton et al. (81) . From the observation that o(.-TGdR exhibits antitumour activity, is phosphorylated in tumour cells (but not in bone marrow cells, hence its low toxicity), and is eventually incorporated into short DNA chains as a terminator, it was reasoned, as earlier proposed by Horton and Sakota (82) , that the OH functions at the 3' and 5' of are essentially interchangeable, and that the furanose ring 0 and the 2'-.CH2 are also interchangeable, so that affinity for the tumour kinase(s) should be improved if a primary CH2OH were present at 5' and 3'. This led to the synthesis of the 3'-.H2OH derivatives of -. and -.TGdR (Fig. 10) . Both of these were, in fact, significantly and equally more active, and were phosphorylated and incorporated into DNA (as chain terminators) 3-fold more rapidly than -TGdR. Furthermore, nucleotides of the three foregoing were totally cleaved by 5'-nucleotidase, an enzyme system for which some conformational requirements have been reported (83) . Although it was subsequently found that the Q(-TGdR is too toxic (because it is phosphorylated by bone marrow kinases), this problem is worthy of further investigation, particularly from an enzymological point of view, as pointed out else--where (84). 3'-Branched nucleosides are usually obtained by prior prepar--ation of the branched sugar and condensation with the appropriate base ring-expansion and reconstitution of the ribose moiety, probably app1ic-able to other nucleosides. Furthermore, the foregoThg underlines once again the utility of examining the potential antirnetabolic properties of the O(-anomers of nucleosides, pointed out some years ago (86) , and now being actively pursued in some laboratories (e.g. ref. 87 ).
Dihjdroyprpyladenine and 9-dihdroxybutylguanine
In contrast to acycloG and DBPG, these acyclonucleoside analogues retain the lower portion of the pentose ring (see Fig. 10 ). ()-9-'(2,3-dihydroxy-. propyl)adenine, but not the R enantiomer, is active against a number of RNA and DNA viruses, but at considerably higher concentrations than acycloG or DHPG. It was the only one, out of 68 analogues with various heterocyclic bases and with numerous modifications of the acyclic moiety, to exhibit such activity (88) . Its mode of action has not been elucidated, but must obviously differ from those of ACG and DHPG. It has hitherto not been considered a candidate for clinical trials. By contrast, modification and extension of the acyclic moiety to include a terminal primary bydroxyl, with guariine as the base residue, led to 9-.(3,4-dihydroxybutyl)guanine, which proved a reasonably good in vitro inhibitor of HSV-.1 and 2, and reasonably effective in animal trials, the F enantiomer being more inhib-.
itory than the (89) . Its mode of action, like that of ACG, appears to involve phosphorylation, initially by the HSV kinase, and subsequent inhibition of viral DNA synthesis. It should be noted that it had previously been found that 9-[()-.3,4-.dihydroxybuty1] adenine is inactive (88), most likely because it was not a substrate for the viral kinase.
Additional activities of acyclonuc1eosides
In addition to antiviral activity, acyclonucleosides and nucleotides have been found to exhibit some interesting properties in other enzyme systems. (91, 92) . Furthermore EHNA itself exhibits potent antiviral activity (91), although its mechanism of action is not known.
More recently it was found tbat 1-(2-.hydroxyethoxymethyl) derivatives of uracil and some 5-substituted uracils are fairly good inhibitors of uridine phosphorylase, the most potent being acyclothymine, with a Ki of 3 pM for inhibition of phosphorolysis (the reverse synthetic reaction was not studied). By combining this property with the known inhibitory properties of 5-benzyluracil and 5.-benzyloxybenzyluracil, Niedzwicki et al. (93) were led to the 1-'(2-hydroxyethoxyinethyl) analogue of 5-benzyloxybenzyluracil, presently the most potent inhibitor of uridine phosphorylase (K"30 EM), at least for the phosphorylytic reaction. The inhibition is fairly specific, inasmuch as there was no significant effect on thymidine phosphorylase. It would be of interest to examine the effects of these compounds on uridine-. -thymidine phosphorylase. In a study still in progress, we have both confirmed and extended the foregoing results with a highly purified uridine phosphorylase from E. coli (A. Drabikowska et al., in preparation). The inhibitory properties of the foregoing analogues are of considerable intereat in relation to their conformational properties on interaction with the enzyme, since it has been shown that phosphorolysis of uridine, and 5-substituted uridines, proceeds via an intermediate state in the conformation about the glycosidic bonT94).
It has also been reported (95) that acycloG is a weak inhibitor of purine nucleoside phosphorylase (Kj ' 90 pM), but one of its minor intracellular metabolites, 8-hydroxy-acycloG, is much more potent (Ki = 5pM). By contrast, acycloGDP exhibits a Ki of 0.5 pM which, in the presence of 1 mM phosphate (physiological concentration), is reduced to 10 nM, hence the most potent inhibitor of this enzyme presently known. From the measured levels of phosphates of acycloG in different tissues it appeared unlikely that the mode of action of acycloG involves purine nucleoside phosphorylase (PNP). Since one of the major goals in the search for PNP inhibitors is the fact tbat a genetic deficiency of this enzyme is accomp- anied by impaired cellular, but not humoral, immunity, it was noted that the use of doses 10-40.-fold higher than that recommended for systemic use as an antiviral agent apparent1 has little or no effect on a variety of immunere1ated functions in vivo (95) . In a study currently under way in our laboratories, with the aUf a new continuous fluorimetric assay for PNP (E. Kulikowska et al., in preparation), it has been found that DHPG is about 3..fo1d more effective an inhibitor than acycloG, and 2',3'seca guanosine equally or slightly more effective.
Conformational aspects. The acyclonucleosides exhibited in Fig. 10 are depictea in sucb a manner as to illustrate the possible resemblance of the acyclic chain to the pentose ring. For each of the analogues shown this is, obviously only one of a multitude of possible equilibrium conformations in solution. It will clearly be of interest to establish the specific conf orination adopted by each of these on interaction with an appropriate enzyme for which it is either a substrate or inhibitor, e.g. the HSV thymidine kinases. The development of a recombinant procedure for cloning HSV-1 thymidine kinase in . coil (96) 
TARGETS FOR ATIVIRAL ACTION
From the rather brief account presented above, it must be admitted that more satisfactory antiviral agents are still an important goal, and we are far from possessing a drug that even approaches the level of one of the common antibiotics. On the other hand, a good deal has been learnt about the steps required in further research, particularly about the nature of at least some of the "targets" which might be effectively attacked; and a recent symposium, devoted entirely to this subject (99) , includes an overall survey of possible targets for viral chemotherapy (100). Although several compounds are now known which inhibit such processes as uncoating, assembly, etc. (see above), the major emphasis at the moment is on viral--encoded enzymes, a good example being PFA, which appears to act largely as a preferential inhibitor of herpes simplex DNA polymerase. It is therefore to be anticipated that isolation, and characterization of the properties of, viral enzymes is one of the important requirements for further progress. This is exemplified by current studies on the ribonucleotide reductases of HSV-1, HSV-2 and pseudorabies virus (101, 102, 103) . Meanwhile there are already a number of examples of the use of highly sensitive enzyme assays for the rapid clinical diagnosis of virus infections, based on detection in physiological fluids of a specific viral enzyme, e.g. diagnosis of varicella-zoster virus infection by monitoring the level of viral thymidine kinase in serum and vesicle fluids (104) . The above-mentioned ribonucleotide reductases are equally sufficiently different in various properties from the corresponding cellular enzymes as to permit of such applications, as are other enzymes referred to above, such as RNA and DNA polymerases.
